全文获取类型
收费全文 | 30933篇 |
免费 | 1260篇 |
国内免费 | 155篇 |
专业分类
耳鼻咽喉 | 331篇 |
儿科学 | 925篇 |
妇产科学 | 789篇 |
基础医学 | 3041篇 |
口腔科学 | 985篇 |
临床医学 | 2745篇 |
内科学 | 6606篇 |
皮肤病学 | 543篇 |
神经病学 | 1850篇 |
特种医学 | 1067篇 |
外国民族医学 | 4篇 |
外科学 | 5513篇 |
综合类 | 699篇 |
现状与发展 | 2篇 |
一般理论 | 22篇 |
预防医学 | 2034篇 |
眼科学 | 1087篇 |
药学 | 2339篇 |
10篇 | |
中国医学 | 224篇 |
肿瘤学 | 1532篇 |
出版年
2024年 | 212篇 |
2023年 | 387篇 |
2022年 | 876篇 |
2021年 | 1397篇 |
2020年 | 892篇 |
2019年 | 1057篇 |
2018年 | 1263篇 |
2017年 | 931篇 |
2016年 | 996篇 |
2015年 | 1042篇 |
2014年 | 1363篇 |
2013年 | 1676篇 |
2012年 | 2500篇 |
2011年 | 2410篇 |
2010年 | 1380篇 |
2009年 | 1167篇 |
2008年 | 1815篇 |
2007年 | 1828篇 |
2006年 | 1634篇 |
2005年 | 1441篇 |
2004年 | 1309篇 |
2003年 | 1082篇 |
2002年 | 962篇 |
2001年 | 294篇 |
2000年 | 249篇 |
1999年 | 221篇 |
1998年 | 164篇 |
1997年 | 108篇 |
1996年 | 101篇 |
1995年 | 90篇 |
1994年 | 77篇 |
1993年 | 61篇 |
1992年 | 125篇 |
1991年 | 134篇 |
1990年 | 95篇 |
1989年 | 107篇 |
1988年 | 85篇 |
1987年 | 78篇 |
1986年 | 76篇 |
1985年 | 103篇 |
1984年 | 65篇 |
1983年 | 41篇 |
1982年 | 46篇 |
1981年 | 49篇 |
1980年 | 35篇 |
1979年 | 38篇 |
1978年 | 36篇 |
1976年 | 30篇 |
1975年 | 30篇 |
1973年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Inna Y. Gong Nigel S. Tan Sammy H. Ali Gerald Lebovic Muhammad Mamdani Shaun G. Goodman Dennis T. Ko Andreas Laupacis Andrew T. Yan 《The Canadian journal of cardiology》2019,35(5):653-660
Background
Although it is known that women do not participate in trials as frequently as men, there are limited recent data examining how women recruitment has changed over time.Methods
We conducted MEDLINE search using a validated strategy for randomized trials published in New England Journal of Medicine, Lancet, and Journal of the American Medical Association between 1986 and 2015, and included trials evaluating pharmacologic or nonpharmacologic therapies. We abstracted data on demographics, intervention type, clinical indication, and trial design characteristics, and examined their relationships with women enrollment.Results
In total, 598 trials met inclusion criteria. Women enrollment increased significantly over time (21% between 1986 and 1990 to 33% between 2011 and 2015; Pfor trend < 0.001) and did not differ by journal or funding source. Women enrollment varied with clinical indication, comprising 37% for non–coronary artery disease vascular trials, 30% for coronary artery disease trials, 28% for heart failure trials, and 28% for arrhythmia trials (P < 0.001), which were all significantly lower than the expected proportion in disease populations (P < 0.001). Women enrollment varied with trial type (31%, 29%, and 26% for pharmacologic, device, and procedural trials, respectively; P = 0.001). These findings were corroborated using multivariable analysis. We found significant positive correlations between women enrolled, and mean age and total number of participants. Fewer women were enrolled in trials reporting statistically significant results than those who did not (P = 0.001).Conclusions
Although enrollment of women has increased over time, it remains lower than the relative proportion in the disease population. Future studies should elucidate the reasons for persistent under-representation of women in clinical trials. 相似文献2.
Hemolytic disease of fetus and newborn (HDFN) imposes great healthcare burden being associated with maternal alloimmunization against parental-inherited fetal red blood cell antigens causing fetal anemia or death. Noninvasive prenatal analysis (NIPT) provides safe fetal RHD genotyping for early identification of risk pregnancies and proper management guidance. We aimed to conduct systematic review and meta-analysis on NIPT's beneficial application, in conjunction with quantitative maternal alloantibody analysis, for early diagnosis of pregnancies at risk. Search for relevant articles was done in; PubMed/Medline, Scopus, and Ovid (January 2006April 2020), including only English-written articles reporting reference tests and accuracy data. Nineteen eligible studies were critically appraised. NIPT was estimated highly sensitive/specific for fetal RHD genotyping beyond 11-week gestation. Amplifications from ≥2 exons are optimum to increase accuracy. NIPT permits cost-effectiveness, precious resources sparing, and low emotional stress. Knowledge of parental ethnicity is important for correct NIPT result interpretations and quantitative screening. Cut-off titer ≥8-up-to-32 is relevant for anti-D alloantibodies, while, lower titer is for anti-K. Alloimmunization is influenced by maternal RHD status, gravida status, and history of adverse obstetrics. In conclusion, NIPT allows evidence-based provision of routine anti-D immunoprophylaxis and estimates potential fetal risks for guiding further interventions. Future large-scale studies investigating NIPT's non-RHD genotyping within different ethnic groups and in presence of clinically significant alloantibodies are needed. 相似文献
3.
Eman Hamid MD PhD Biniyam A. Ayele MD Daniel Gams Massi MD Samia Ben Sassi MD Houyam Tibar MD Emmanuel Epenge Djonga MD Sarah Misbah El-Sadig MD Wahiba AMER EL KHEDOUD MD Julien Razafimahefa MSc Ange Eric Kouame-Assouan MD Djibrilla Ben-Adji MD Yilédoma Thierry Modeste Lengané MD Abdu Kisekka Musubire MD Muhyadin Hassan Mohamed MSc Tiwonge Elisa Phiri MBBS FCN Nsengiyumva Nestor MD Wael Abdulgader Alwahchi MSc Saara Ndinelago Neshuku MBChB FCN MMed Cassandra Ocampo MD Foksouna Sakadi MD Moulid Ali Maidal MBBS Gift Wilson Ngwende MBChB MMed FCP Juzor Hooker MB ChB MMed DCN FCP Kigocha Okeng'o MD Med MSc Augustina Charway-Felli MD PhD FGCPS Masharip Atadzhanov PhD FRCP Jonathan Carr MBChB PhD Njideka U. Okubadejo MBChB FMCP FAAN Ali Shalash MD PhD 《Movement disorders》2021,36(10):2393-2407
4.
5.
6.
Javariya Aamir Syed Mustafa Ali Maged N. Kamel Boulos Naveed Anjum Muhammad Ishaq 《Health Policy and Technology》2018,7(1):88-97
Objective
The objective of this review is to identify enabling and inhibiting factors for mHealth adoption in low resource settings, by giving emphasis on the stakeholders representing the caregiving side. Another objective of this study is to support implementation agencies (governmental and non-governmental) in designing scalable mHealth interventions.Methods
A PEO (Population, Exposure, Outcome) approach was used to formulate the review question. A pre-defined search strategy was implemented; Google Scholar, PubMed and gray literature were searched using alternate terms for “mHealth”, “adoption” and “developing countries”. CASP [7] tools were used to assess the quality of selected evidence. After applying inclusion and exclusion criteria on search results and critical appraisal of the selected evidence, twelve studies were selected for the review.Results
Adoption factors operated at the levels of organization, facility-based service provider and frontline health worker. Engagement of end users during design phase, informed clinical decision making, utilization of mHealth evidence, employers’ tolerance of some personal use of devices, automation of tasks and user-friendliness of application are key enabling factors for mHealth adoption in developing countries. On the contrary, absence of national policy on mHealth, poor knowledge base on mHealth, using two systems in parallel, duplication of efforts, poor Internet connectivity and shortage of electricity are important inhibiting factors for mHealth adoption.Conclusions
The review provides an insight about the challenges and opportunities related to mHealth adoption in developing countries. Implementation agencies should give careful consideration to these factors before designing and deploying any mHealth-enabled intervention. It is also important to understand the concept of incremental innovation so that resources spent on pilot interventions are optimized and full potential is achieved. 相似文献7.
8.
Ali Ramazani Mojtaba Keramati Hojat Malvandi 《Pharmaceutical development and technology》2018,23(9):911-920
AbstractPurpose: Artemisinin (ART) has anti-inflammatory, antimicrobial, antioxidant, anti-amyloid, and anti-malarial effects, but its application is limited due to its low water solubility and poor oral bioavailability. In this study, the bioavailability, water solubility, and anti-plasmodial property of ART were improved by PCL–PEG–PCL tri-block copolymers.Methods: The structure of the copolymers was characterized by 1H NMR, FT-IR, DSC, and GPC techniques. ART was encapsulated within micelles by a single-step nano-precipitation method, leading to the formation of ART-loaded PCL–PEG–PCL micelles. The obtained micelles were characterized by dynamic light scattering (DLS) and atomic force microscopy (AFM). The in vivo anti-plasmodial activity of ART-loaded micelles was measured against Plasmodium berghei infected Swiss albino mice.Results: The results showed that the zeta potential of ART-loaded micelles was about ?8.37?mV and the average size was 91.87?nm. ART was encapsulated into PCL–PEG–PCL micelles with a loading capacity of 19.33?±?0.015% and encapsulation efficacy of 87.21?±?3.32%. In vivo anti-plasmodial results against P. berghei showed that multiple injections of ART-loaded micelles could prolong the circulation time and increase the therapeutic efficacy of ART.Conclusion: These results suggested that PCL–PEG–PCL micelles would be a potential carrier for ART for the treatment of malaria. 相似文献
9.
Afzal Hussain Perwez Alam Nasir Ali Siddiqui Mohamed Fahad Alajmi Md Tabish Rehman Mohd Abul Kalam Adnan Jathlan Al-Rehaily 《Saudi Pharmaceutical Journal》2018,26(7):970-976
Bergenin and menisdaurin are biologically active components which are found in plant Flueggea virosa (Phyllanthaceae). Bergenin has pharmacological actions such as chemopreventive and antihepatotoxic while menisdaurin has an anti-viral activity which needs its evaluation by an analytical method (UPLC-PDA method) that can be applied to the quality control of pharmaceutical preparations. The developed UPLC-PDA method was applied for identification and quantification of standards bergenin and menisdaurin in the methanol extract of F. virosa (FVME). The analysis was carried out using Eclipse C18 (4.6?×?100?mm, 3.5?µm) UPLC column. The optimized chromatographic condition was achieved at 0.16?mL/min flow rate using gradient system with acetonitrile and water as mobile phase. Both biomarkers were measured at λmax 235?nm in PDA detector at ambient temperature. The developed method furnished sharp and intense peaks of menisdaurin and bergenin at Rt?=?2.723 and 3.068?min, respectively along with r2?>?0.99 for both. The recoveries of bergenin and menisdaurin were found in the range of 99.37–101.49% and 98.20–100.08%, respectively. With other validation data, including precision, specificity, accuracy, and robustness, this method demonstrated excellent reliability and sensitivity. The separation parameters i.e. retention, separation, and resolution factors for resolved standards (bergenin and menisdaurin) were >1, which showed good separation. The quantity of bergenin and menisdaurin in the FVME sample was found as 15.16 and 3.28% w/w, respectively. The developed UPLC-PDA method could be conveniently adopted for the routine quality control analysis. 相似文献
10.